Nervenheilkunde 2015; 34(11): 871-877
DOI: 10.1055/s-0038-1627645
Schattauer GmbH

Depression bei Frauen

Wochenbettdepression und perimenopausale DepressionDepression across the reproductive cyclePostpartum and perimenopausal depression
S. Krüger
1   Zentrum für Seelische Frauengesundheit, Vivantes Humboldt Klinikum Berlin
› Author Affiliations
Further Information

Publication History

eingegangen am: 07 July 2015

angenommen am: 15 July 2015

Publication Date:
22 January 2018 (online)


Frauen leiden häufig im Zusammenhang mit reproduktiven Ereignissen, also vor der Menstruation, während und nach der Schwangerschaft und in den Wechseljahren an affektiven Erkrankungen. Dieses liegt an den komplexen Zusammenhängen zwischen weiblichen Geschlechtshormonen und Neurotransmittern, aber natürlich auch an den Einflüssen belastender oder sich verändernder Lebensumstände. Affektive Symptome können in diesen Zusammenhängen erstmals manifest werden, und in Symptomausprägung oder Schwere variieren. Wochenbetterkrankungen betreffen fast 20% aller Frauen und bergen das Risiko der Schädigung des Kindes durch Vernachlässigung, durch komorbide Zwangssymptome und im extremen Fall durch Infantizid. Die Ursachen der Wochenbettdepression, die sich meist sechs Wochen nach der Geburt manifestiert, sind nicht geklärt. Die Therapie umfasst psychopharmakologische und psychotherapeutische Interventionen, erstere in Abhängigkeit davon, ob die Patientin stillen kann oder möchte. Die Perimenopause ist im Leben einer Frau die Zeit mit dem höchsten Depressionsund Angsterkrankungsrisiko. Hier sind die Zusammenhänge zwischen hormonellen Veränderungen und der psychischen Symptomatik gut belegt. Behandlungsstrategien beinhalten demnach sowohl hormonelle als auch psychopharmakologische, in manchen Fällen auch psychotherapeutische Interventionen.


Reproductive events including the postpartum and perimenopause are a major risk factor for the development of depression and anxiety in women. This is due to the complex relations between female hormones and neurotransmitters as well as to life events after birth and in midlife. Affective disorders can both become manifest for the first time in the woman’s life or show an aggravation in frequency and severity during these times. Postpartum depression affects up to 20% of women and occurs about 6 weeks after delivery. It is highly associated with harming the baby either because of neglect, comorbid obsessive-compulsive symptoms or in the worst case because of infanticide. The etiology of postpartum depression is not entirely clear – hormonal changes alone do not account for it. Treatment comprises psychopharmacological and psychological interventions, the former depending on whether the woman can or wants to nurse. Perimenopausal depression on the other hand is clearly associated with changes in hormonal levels, it affects about 20% of women and comprises both physical and psychological symptoms of menopause, which interfere with each other. Treatment comprises hormonal, psychopharmacological and in some cases psychotherapeutic interventions.

  • Literatur

  • 1 Payne JL, Roy PS, Murphy-Eberenz K, Weismann MM, Swartz KL, McInnis MG, Nwulia E, Mondimore FM, MacKinnon DF, Miller EB, Nurnberger JI, Levinson DF, DePaulo Jr JR, Potash JB. Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. J Affect Disord 2007; 99 1–3 221-9.
  • 2 Soares CN, Zitek B. Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability?. J Psychiatry Neurosci 2008; 33 (04) 331-43.
  • 3 Bristot G, Ascoli B, Gubert C, Panizzutti B, Kapczinski F, Rosa AR. Progesterone and its metabolites as therapeutic targets in psychiatric disorders. Expert Opin Ther Targets 2014; 18 (06) 679-90.
  • 4 Quast C, Reif A, Brückl T, Pfister H, Weber H, Mattheisen M, Cichon S, Lang T, Hamm A, Fehm L, Ströhle A, Arolt V, Domschke K, Kircher T, Wittchen HU, Pauli P, Gerlach AL, Alpers GW, Deckert J, Rupprecht R, Binder EB, Erhardt A. Gender-specific association of variants in the AKR1C1 gene with dimensional anxiety in patients with panic disorder: additional evidence for the importance of neurosteroids in anxiety?. Depress Anxiety 2014; 31 (10) 843-50.
  • 5 Schüle C, Nothdurfter C, Rupprecht R. The role of allopregnanolone in depression and anxiety. Prog Neurobiol 2014; 113: 79-87.
  • 6 Schumacher M, Mattern C, Ghoumari A, Oudinet JP, Liere P, Labombarda F, Sitruk-Ware R, De Nicola AF, Guennoun R. Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors. Prog Neurobiol 2014; 113: 6-39.
  • 7 Hall E, Steiner M. Serotonin and female psychopathology. Womens Health (Lond Engl) 2013; 09 (01) 85-97.
  • 8 Ryan J, Ancelin ML. Polymorphisms of estrogen receptors and risk of depression: therapeutic implications. Drugs 2012; 72 (13) 1725-38.
  • 9 Bei B, Coo S, Trinder J. Sleep and mood during pregnancy and the postpartum period. Sleep Med Clin 2015; 10 (01) 25-33.
  • 10 Maimburg RD, Væth M. Postpartum depression among first-time mothers – results from a parallel randomised trial. Sex Reprod Healthc 2015; 06 (02) 95-100.
  • 11 Norhayati MN, Hazlina NH, Asrenee AR, Emilin WM. Magnitude and risk factors for postpartum symptoms: a literature review. J Affect Disord 2015; 175: 34-52.
  • 12 Pope CJ, Sharma V, Mazmanian D. Recognition, diagnosis and treatment of postpartum bipolar depression. Expert Rev Neurother 2014; 14 (01) 19-28.
  • 13 Rallis S, Skouteris H, McCabe M, Milgrom J. The transition to motherhood: towards a broader understanding of perinatal distress. Women Birth 2014; 27 (01) 68-71.
  • 14 Azam S, Khanam A, Tirlapur S, Khan K. Planned caesarean section or trial of vaginal delivery? A meta-analysis. Curr Opin Obstet Gynecol 2014; 26 (06) 461-466.
  • 15 Couto TC, Brancaglion MY, Alvim-Soares A, Moreira L, Garcia FD, Nicolato R, Aguiar RA, Leite HV, Corrêa H. Postpartum depression: A systematic review of the genetics involved. World J Psychiatry 2015; 05 (01) 103-11.
  • 16 Barakat S, Martinez D, Thomas M, Handley M. What do we know about gestational diabetes mellitus and risk for postpartum depression among ethnically diverse low-income women in the USA?. Arch Womens Ment Health 2014; 17 (06) 587-92.
  • 17 DelRosario GA, Chang AC, Lee ED. Postpartum depression: symptoms, diagnosis, and treatment approaches. JAAPA 2013; 26 (02) 50-4.
  • 18 Speisman BB, Storch EA, Abramowitz JS. Postpartum obsessive-compulsive disorder. J Obstet Gynecol Neonatal Nurs 2011; 40 (06) 680-90.
  • 19 Spinelli MG. Infanticide: contrasting views. Arch Womens Ment Health 2005; 08 (01) 15-24.
  • 20 Spinelli MG. Maternal infanticide associated with mental illness: prevention and the promise of saved lives. Am J Psychiatry 2004; 161 (09) 1548-57.
  • 21 Trautmann-Villalba P, Hornstein C. Children murdered by their mothers in the postpartum period. Nervenarzt 2007; 78 (11) 1290-5.
  • 22 Molynaux E, Howard LM, McGeown HR, Karia AM, Trevillion K. Antidepressant treatment for postnatal depression. Cochrane Database Syst Rev. 2014 09. CD002018.
  • 23 Brandon AR, Crowley SK, Gordon JL, Girdler SS. Nonpharmacologic treatments for depression related to reproductive events. Curr Psychiatry Rep 2014; 16 (12) 526-540.
  • 24 Crowley SK, Youngstedt SD. Efficacy of light therapy for perinatal depression: a review. J Physiol Anthropol 2012; 31: 15-36.
  • 25 Studd JW. A guide to the treatment of depression in women by estrogens. Climacteric 2011; 14 (06) 637-42.
  • 26 Dennis CL, Ross LE, Herxheimer A. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane Database Syst Rev. 2008 (4): CD001690.
  • 27 Kim DR, Epperson CN, Weiss AR, Wisner KL. Pharmacotherapy of postpartum depression: an update. Expert Opin Pharmacother 2014; 15 (09) 1223-34.
  • 28 Meltzer-Brody S. New insights into perinatal depression: pathogenesis and treatment during pregnancy and postpartum. Dialogues Clin Neurosci 2011; 13 (01) 89-100.
  • 29 Stuart-Parrigon K, Stuart S. Perinatal depression: an update and overview. Curr Psychiatry Rep 2014; 16 (09) 468-492.
  • 30 McDonagh MS, Matthews A, Phillipi C, Romm J, Peterson K, Thakurta S, Guise JM. Depression drug treatment outcomes in pregnancy and the postpartum period: a systematic review and metaanalysis. Obstet Gynecol 2014; 124 (03) 526-34.
  • 31 O’Reardon JP, Cristancho MA, von Andreae CV, Cristancho P, Weiss D. Acute and maintenance electroconvulsive therapy for treatment of severe major depression during the second and third trimesters of pregnancy with infant follow-up to 18 months: case report and review of the literature. J ECT 2011; 27 (01) e23-31.
  • 32 Levy Y, Austin MP, Halliday G. Use of ultra-brief pulse electroconvulsive therapy to treat severe postnatal mood disorder. Australas Psychiatry 2012; 20 (05) 429-32.
  • 33 Sockol LE. A systematic review of the efficacy of cognitive behavioral therapy for treating and preventing perinatal depression. J Affect Disord 2015; 177: 7-21.
  • 34 Soares CN. Depression in periand postmenopausal women: prevalence, pathophysiology and pharmacological management. Drugs Aging 2013; 30 (09) 677-85.
  • 35 Gordon JL, Girdler SS, Meltzer-Brody SE, Stika CS, Thurston RC, Clark CT, Prairie BA, Moses-Kolko E, Joffe H, Wisner KL. Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model. Am J Psychiatry 2015; 172 (03) 227-36.
  • 36 Parry BL, Newton RP. Chronobiological basis of female-specific mood disorders. Neuropsychopharmacology 2001; 25 (05) S102-8.
  • 37 Worsley R, Bell R, Kulkarni J, Davis SR. The association between vasomotor symptoms and depression during perimenopause: a systematic review. Maturitas 2014; 77 (02) 111-7.
  • 38 Gibbs Z, Lee S, Kulkarni J. What factors determine whether a woman becomes depressed during the perimenopause?. Arch Womens Ment Health 2012; 15 (05) 323-32.
  • 39 Kraepelin E. Psychiatrie. Ein Lehrbuch für Studierende und Ärzte. 6. Auflage. Leipzig: Barth; 1899: 34-5.
  • 40 Bromberger JT, Kravitz HM. Mood and menopause: findings from the Study of Women’s Health Across the Nation (SWAN) over 10 years. Obstet Gynecol Clin North Am 2011; 38 (03) 609-25.
  • 41 Rubinow DR, Girdler SS. Hormones, heart disease, and health: individualized medicine versus throwing the baby out with the bathwater. Depress Anxiety 2011; 28 (04) 282-96.
  • 42 Burt VK, Quezada V. Mood disorders in women: focus on reproductive psychiatry in the 21st century – Motherisk update 2008. Can J Clin Pharmacol 2009; 16 (01) e6-e14.
  • 43 Gordon JL, Girdler SS. Hormone replacement therapy in the treatment of perimenopausal depression. Curr Psychiatry Rep 2014; 16 (12) 517.
  • 44 Borrow AP, Cameron NM. Estrogenic mediation of serotonergic and neurotrophic systems: implications for female mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2014; 54: 13-25.
  • 45 Mendoza N, Sanchez-Borrego R. Classical and newly recognised non-contraceptive benefits of combined hormonal contraceptive use in women over 40. Maturitas 2014; 78 (01) 45-50.
  • 46 Worsley R, Davis SR, Gavrilidis E, Gibbs Z, Lee S, Burger H, Kulkarni J. Hormonal therapies for new onset and relapsed depression during perimenopause. Maturitas 2012; 73 (02) 127-33.
  • 47 Graziottin A, Serafini A. Depression and the menopause: why antidepressants are not enough?. Menopause Int 2009; 15 (02) 76-81.
  • 48 Schmidt PJ, Rubinow DR. Sex hormones and mood in the perimenopause. Ann N Y Acad Sci 2009; 1179: 70-85.
  • 49 Wise DD, Felker A, Stahl SM. Tailoring treatment of depression for women across the reproductive lifecycle: the importance of pregnancy, vasomotor symptoms, and other estrogen-related events in psychopharmacology. CNS Spectr 2008; 13 (08) 647-62.
  • 50 Toffol E, Heikinheimo O, Partonen T. Hormone therapy and mood in perimenopausal and postmenopausal women: a narrative review. Menopause 2015; 22 (05) 564-78.
  • 51 Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, Rubinow DR. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000; 183 (02) 414-20.
  • 52 Joffe H, Petrillo LF, Koukopoulos A, Viguera AC, Hirschberg A, Nonacs R, Somley B, Pasciullo E, White DP, Hall JE, Cohen LS. Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition. J Clin Endocrinol Metab 2011; 96 (07) E1044-54.
  • 53 Rasgon NL, Altshuler LL, Fairbanks LA, Dunkin JJ, Davtyan C, Elman S, Rapkin AJ. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry 2002; 63 Suppl 7 45-8.
  • 54 Morgan ML, Cook IA, Rapkin AJ, Leuchter AF. Neurophysiologic changes during estrogen augmentation in perimenopausal depression. Maturitas 2007; 56 (01) 54-60.
  • 55 Morgan ML, Cook IA, Rapkin AJ, Leuchter AF. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry 2005; 66 (06) 774-80.
  • 56 Rogines-Velo MP, Heberle AE, Joffe H. Effect of medroxyprogesterone on depressive symptoms in depressed and nondepressed perimenopausal and postmenopausal women after discontinuation of transdermal estradiol therapy. Menopause 2012; 19 (04) 471-5.
  • 57 Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288 (03) 321-33.
  • 58 Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2010; 15 (03) 241-52.
  • 59 Aedo S, Cavada G, Blümel JE, Chedraui P, Fica J, Barriga P, Brantes S, Irribarra C, Vallejo M, Campodónico Í. Women’s Health Initiative estrogen plus progestin clinical trial: a study that does not allow establishing relevant clinical risks. Menopause. 2015 May 11 epub ahead of print.
  • 60 Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W, Menopause and Osteoporosis Working Group, Fortier M, Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Graves L, Guthrie B, Khan A, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W. Menopause and Osteoporosis Working Group. Society of Obstetricians and Gynaecologists of Canada. Managing menopause. J Obstet Gynaecol Can 2014; 36 (09) 830-8.
  • 61 Ensrud KE, Joffe H, Guthrie KA, Larson JC, Reed SD, Newton KM, Sternfeld B, Lacroix AZ, Landis CA, Woods NF, Freeman EW. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause 2012; 19 (08) 848-55.
  • 62 Soares CN, Arsenio H, Joffe H, Bankier B, Cassano P, Petrillo LF, Cohen LS. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic periand postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause 2006; 13 (05) 780-6.
  • 63 Citarella A, Andersen M, Sundström A, Bardage C, Hultman CM, Kieler H. Initiating therapy with antidepressants after discontinuation of hormone therapy. Menopause 2013; 20 (02) 146-51.
  • 64 Iglesias CGarcía, Ocio SLeón, Ortigosa JCDigón, Merino MJGarcía, Alonso MJVilla, Fernández LPalicio, Alonso JLRionda, García FFernández, Rodríguez LColubi, Toimil AIglesias. Comparison of the effectiveness of venlafaxine in periand postmenopausal patients with major depressive disorder. Actas Esp Psiquiatr 2010; 38 (06) 326-31.
  • 65 Vélez MToral, Godoy-Izquierdo D, Padial AGarcía, Lara RMoreno, Mendoza NLadrón de Guevara, Salamanca ABallesteros, de Teresa CGalván, Godoy JFGarcía. Psychosocial interventions in perimenopausal and postmenopausal women: a systematic review of randomised and non-randomised trials and non-controlled studies. Maturitas 2014; 77 (02) 93-110.
  • 66 Norton S, Chilcot J, Hunter MS. Cognitive-behavior therapy for menopausal symptoms (hot flushes and night sweats): moderators and mediators of treatment effects. Menopause 2014; 21 (06) 574-8.
  • 67 Hunter MS. “Beliefs about hot flashes drive treatment benefit”. Menopause 2014; 21 (08) 909.